Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 4/20 | 0.41 |
| ▸ | AGXT | P21549 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 2/20 | 0.40 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874729 | 1.00 | TRPA1 (0.59) | TRPA1SLC6A4LOXL2DPP4DPP7 | |
| SCHEMBL1775840 | 1.00 | TRPA1 (0.59) | TRPA1SLC6A4LOXL2DPP4DPP7 | |
| SCHEMBL3191528 | 0.88 | SLC6A4 (0.58) | TRPA1SLC6A4LOXL2DPP4DPP7 | |
| Methyl Carbamate SCHEMBL28108930 | 0.84 | TRPA1 (0.49) | TRPA1DPP4DPP7 | |
| Hydrochloric Acid SCHEMBL6539906 | 0.84 | TRPA1 (0.45) | TRPA1DPP4DPP7TAAR1 | |
| Hydrochloric Acid SCHEMBL6539897 | 0.84 | TRPA1 (0.45) | TRPA1DPP4DPP7TAAR1 | |
| SCHEMBL15476620 | 0.84 | SLC6A4 (0.48) | TRPA1SLC6A4LOXL2DPP4DPP7 | |
| SCHEMBL5787187 | 0.82 | LOXL2 (0.52) | TRPA1SLC6A4LOXL2DPP4DPP7 | |
| SCHEMBL3614354 | 0.81 | TAAR1 (0.48) | TRPA1SLC6A4LOXL2DPP4TAAR1 | |
| SCHEMBL3614359 | 0.81 | TAAR1 (0.48) | TRPA1SLC6A4LOXL2DPP4TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106458866-A | Aminocarbonyl carbamate compound | 爱思开生物制药株式会社 | 2017-02-22 | — | — | CN | claimed |
| WO-2025124377-A1 | SOLAR CELL, INTERFACE PASSIVATION MATERIAL, PHOTOVOLTAIC POWER GENERATION SYSTEM AND ELECTRIC DEVICE | 宁德时代未来能源(上海)研究院有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-120152597-A | Interface passivation material, solar cell, photovoltaic power generation system and electric equipment | 宁德时代未来能源(上海)研究院有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-106458866-A | Aminocarbonyl carbamate compound | 爱思开生物制药株式会社 | 2017-02-22 | — | — | CN | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-8859563-B2 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2014-10-14 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | AVEXA LIMITED (AU) | 2012-09-13 | — | — | US | disclosed |
| EP-1092435-B1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO KK (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-7005430-B2 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2006-02-28 | — | — | US | disclosed |
| EP-1251130-B1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO KK (JP) | 2005-02-16 | — | — | EP | disclosed |
| US-20030176698-A1 | Fused purine derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-09-18 | — | — | US | disclosed |
| US-6489331-B1 | A CONDENSED PURINE DERIVATIVE AS AN ACTIVE INGREDIENT AS AN ENHANCER OF INSULIN SECRETION AND A MEDICAMENT FOR THE TREATMENT OF DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-12-03 | — | — | US | disclosed |
| EP-1251130-A1 | FUSED PURINE DERIVATIVES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
| US-6274715-B1 | SEMISYNTHETIC MACROLIDES, USEFUL IN BACTERIAL INFECTIONS TREATMENT AND PREVENTION, HAS LESS POTENTIAL FOR DEVELOPING RESISTANCE, IMPROVED OR MODIFIED PROFILES OF DESIRED GRAM-NEGATIVE ACTIVITY | ABBOTT LABORATORIES | 2001-08-14 | — | — | US | disclosed |
| EP-1092435-A1 | REMEDIES FOR DIABETES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2001-04-18 | — | — | EP | disclosed |
| CN-1244202-A | Tricyclic erythromycin derivatives | ABBOTT LAB (US) | 2000-02-09 | — | — | CN | disclosed |
| WO-1997046553-A1 | THROMBIN INHIBITORS | NOVARTIS AG (CH) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176698-A1 | Fused purine derivatives | PNP, NSUN2, CYP2W1 | TRPA1 4602/4885SLC6A4 1160/4885LOXL2 1877/4885 |
| US-20120232035-A1 | Bicyclic pyrimidinones and uses thereof | TPMT, TYMP, DPYD | TRPA1 2606/4885SLC6A4 1324/4885LOXL2 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.